EXPRESSION OF MARKERS OF INTERCELLULAR ADHESION CD44 AND CD24 IN CELLS OF ENDOMETRIAL CARCINOMA WITH HIGH MALIGNANCY POTENTIAL
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-21-3-2019-g.7936Keywords:
CD24, CD44, endometrioid carcinoma, serous carcinoma, uterine cancer, віментинAbstract
Aim: to determine the expression of CD44 and CD24 proteins in samples of endometrioid carcinoma of uteri body, depending on the progression parameters of the tumor process. Object and methods: samples of the surgical material of 66 patients with endometrioid cancer (EC) with an average age of 59.7 ± 5.8 years and 13 patients with serous cancer (SC), with an average age of 63.1 ± 4.2 years. Methods: morphological, immunohistochemical, flow cytospectrometry and statistical. Results of the study showed that the number of tumors with positive expression of CD44 was 58 (87.9%) and CD24 — 95.5%). Expression of CD44 protein was significantly higher in G3 tumors (25.4 ± 2.3%) compared with G2 tumor (14.1 ± 2.0%, p < 0.05) and expression of CD24 protein in G3- and G2-tumors were almost equally high, 48.8 ± 2.7 and 47.9 ± 3.0% respectively. In EC, invasion with < ½ myometrium, the number of cells with CD44 and CD24 expression was 18.5 ± 2.4 and 52.4 ± 3.0%, respectively, and in the case of deep myometrium invasion, respectively, 21.2 ± 2.1 and 46.6 ± 3.3%. The largest number of tumors, which was deeply invasive with myometrium and with aneuploidy, had a CD44–/low/CD24high phenotype and with high index of proliferation — CD44high/CD24high or CD44–/low/CD24high phenotypes, that is, the most aggressive signs of EC were generally associated with high values of glycoprotein CD24. The frequency of SC with the CD44–/low/CD24–/low phenotype was 53.8%, CD44high/CD24high — 38.5%, CD44high/CD24–/low — 7.7%. SC with negative CD44 and positive CD24 expression were not detected. Conclusions: high expression of CD24 in EC are associated with such indicators of cancer malignancy as deep tumor invasion in myometrium, high index of proliferation of tumors сells and aneuploidy. The obtained data suggest that the adhesion molecules CD44 and CD24 can be used as markers for the progression of endometrial cancer.
References
Tajiama H, Ohta T, Kitagawa H, et al. Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44. Oncol Lett 2012; 3: 1189–90.
Puchinskaya MV. Cancer stem cell markers and their prognostic value. Archive Pathologists 2016; 2: 47–54 (in Russian).
Gоjster OS. Role of CD24 gene in tumor growth of different organs and study approaches ways of its study. Oncology 2015; 17 (4): 228–35 (in Ukrainian).
Kim YS. Kaidina AM, Chang J-H, et al. Molecular markers of cancerous stem cells, verified in vivo. Biomed Chemistry 2016; 62 (3): 228–38 (in Russian).
Golubtsova NV, Baryshnikova MA. Markers of the ovarian cancer stem cells. Fundamental Oncology 2016; 4: 18–25.
Chen Ch, Zhao S, Karnad А, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol 2018; 11: 64.
Chekhun SV, Zadvorny TV, Tymovska YuO, et al. СD44+/CD24 — markers of cancer stem cells in patients with breast cancer of different molecular subtypes. Exp Oncol 2015; 37 (1): 58–63.
Eyvazi S, Kazemi B, Dastmalchi S, Bandehpour M. Involvement of CD24 in multiple cancer related pathways makes it an interesting new target for cancer therapy. Current Cancer Drug Targets 2018; 18 (4): 328–36 (in Russian).
Levchenko NO, Laktionov KP, Tayipov MA, et al. Molecular markers of endometrial cancer. Tumors Female Reprod Syst 2013; 3–4: 86–9 (in Russian).
Krakmal NV, Zavyalova MV, Denisov EV, et al. Invasion of tumor epithelial cells: mechanisms and manifestation. Acta Naturae 2015; 7 (2): 18–21 (in Russian).
Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Сonference on еndometrial сancer: diagnosis, treatment and follow-up. Ann Oncol 2016; 27: 16–41.
Kurman RJ, Carcangiu M, Herrington CS, Young RH. WHO Classification of Tumours of the Female Reproductive Organs (IARC WHO Classification of Tumours). 4th Edition Series: IARC Press, 2014. 307 p.
Nicoletti GA, Migliorati M, Pagliacci C, et al. А repid and simpl method for measuring thymocyte apoptosis by propidium iodide staining and flou cytometry. J Immunol Methods 1991; 139: 271–9.
Nesina IP, Iurchenko NP, Buchynska LG. Markers of the epithelial-mesenchymal transition in cells of endometrial carcinoma. Exp Oncol 2018; 40 (3): 218–22.
Mylona E, Giannopoulou I, Fasomytakis E, et al. The clinicopathologic and prognostic significance of CD44+/CD24—/low) and CD44—/CD24+ tumor cells in invasive breast carcinomas. Hum Pathol 2008; 39: 1096–1102.
Huang H-H, Wang Yu-Ch, Chou Yu-Ch, et al. The combination of aldehyde dehydrogenase 1 (ALDH1) and CD44 is associated with poor outcomes in endometrial cancer. PLоS ONE 2018; 13 (10): е0206685. https://doi.org/10.1371/journal.pone е0206685.
Ahmad F, Dina K, Faina B, et al. CD24 іnduces the аctivation of β-сatenin in іntestinal tumorigenesis. J Cancer Sci Ther 2016; 8: 135–42.
Wang R, Sun Q, Wang P, et al. Notch and Wnt/β-catenin signaling pathway play important roles in activating liver cancer stem cells. Oncotarget 2016; 7 (5): 5754–68.
Davidson B. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells. Hum Pathol 2016; 58: 123–7.
